anti-atopic

Tranilast (SB 252218), an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of allergic disorders.

Oxazolone is a haptenating agent that can induce models of acute or chronic colitis and atopic dermatitis. It activates Th1/Th2 responses, leading to weight loss and diarrhea, and the resulting inflammation can be alleviated by anti-IL-4 antibodies, anti-TNF-α antibodies, or IL-13R2α-Fc fusion proteins. It is also suitable for studying gene expression related to inflammatory bowel disease in zebrafish.

GLPG2534 is an orally active, selective and potent IRAK4 inhibitor with anti-inflammatory activity. GLPG2534 inhibits human and mouse IRAK4 and could be used to study psoriasis and atopic dermatitis.

Clobetasone butyrate, a synthetic glucocorticoid with topical anti-inflammatory activity, is effective in treating corticosteroid-responsive dermatoses, such as atopic dermatitis and psoriasis, especially within skin tissues.

Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug developed for the treatment of skin diseases.

Mapracorat (ZK-245186, BOL-303242X) is a selective glucocorticoid receptor agonist commonly used as an anti-inflammatory agent for atopic dermatitis, post-cataract surgery inflammation, and allergic conjunctivitis.

JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).

PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.

HDAC6-IN-55 (Compound 15B) is a potent HDAC6 inhibitor and an effective anti-inflammatory agent. It mitigates inflammation through the TLR4/MAPK, STAT3, and NF-κB pathways, providing relief from atopic dermatitis. HDAC6-IN-55 alleviates symptoms such as skin edema, dryness, crusting, and peeling in mice with atopic dermatitis induced by 2,4-dinitrochlorobenzene (DNCB).

JAK3-IN-17 is an orally active JAK3 inhibitor with an IC50 of 14.56 nM. It demonstrates anti-inflammatory activity by inhibiting the production of IL-2 and IL-6 in a DNCB-induced mouse model of atopic dermatitis.

PARP14 inhibitor2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of less than 30 nM. It effectively inhibits the mono ADP-ribosyltransferase activity of PARP14 and modulates IFN-γ and IL-4 signaling, thereby reversing pro-tumor macrophage polarization and suppressing anti-tumor inflammatory responses. PARP14 inhibitor2 holds potential for research in PARP14-related conditions such as tumors, atopic dermatitis, and autoimmune diseases.

Pimecrolimus (SDZ-ASM 981), a calcineurin inhibitor immunosuppressant, binds to the receptor macrophilin-12 (FKBP-12) forming a complex that blocks the calcium-dependent signal transduction cascade mediated by calcineurin.

As a tricyclic antidepressant, Doxepin inhibits the reuptake of serotonin and norepinephrine. Doxepin shows therapeutic effects on atopic dermatitis and chronic urticaria that also improves cognitive processes as well as protect the central nervous system. Doxepin has anti-inflammatory effects and reduces oxidative stress[1] [2] [3].

Benvitimod is a non-steroidal anti-inflammatory drug (NSAID) potentially for the treatment of atopic dermatitis.

1. Eriodictyol (Huazhongilexone) is a flavonoid with anti-inflammatory and antioxidant activities. 2. Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance. 3. Eriodictyol may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis.

Tralokinumab is a fully human IgG4 monoclonal antibody with a high affinity for IL-13 alone. Tralokinumab's potential anti-inflammatory activity prevents IL-13 receptor interaction and subsequent downstream signaling and can be used to study atopic dermatitis (AD).

Lokivetmab, an Anti-Canine IL31 Recombinant Antibody, is a monoclonal antibody targeting canine IL-31, utilized in research related to atopic dermatitis (AD) in dogs [1].

Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways. Spesolimab can be used to study systemic pustular psoriasis, palmar and plantar impetigo (PPP), and atopic dermatitis.

Apamistamab (Anti-CD45 antibody) is a humanized antibody targeting CD45, which can be used to study atopic dermatitis.

Rocatinlimab represents a highly specialized humanized IgG1 monoclonal antibody specifically engineered to target the OX40 receptor (CD134) with exceptional binding affinity. It effectively facilitates the measurable blockade of the OX40-OX40L co-stimulatory axis while simultaneously inducing the targeted depletion of OX40-positive activated T cells through antibody-dependent cellular cytotoxicity (ADCC) across various preclinical experimental models to evaluate the restoration of immune homeostasis during strictly monitored laboratory observation periods.

Anti-IL-13 Antibody (M1295) is a potent neutralizing antibody targeting human interleukin-13 (IL-13), acting by blocking the binding of IL-13 to its receptor complex. The compound is an essential tool for investigating Type 2 immune responses and the pathogenesis of bronchial asthma and atopic dermatitis, aiming to inhibit allergic inflammatory processes by downregulating IL-13-mediated signaling cascades.

Anti-IL-13 Antibody (H2L6) is a humanized monoclonal antibody specifically targeting human interleukin-13 (IL-13). The compound binds to IL-13 with high affinity, effectively blocking its interaction with the receptor complex (IL-13Ra1 and IL-4Ra), thereby inhibiting downstream signaling such as STAT6 phosphorylation. As IL-13 is a key driver of Th2-mediated immune responses, H2L6 is widely utilized in preclinical research for asthma, atopic dermatitis, and other allergic or inflammatory disorders.

MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. It works by specifically binding to IL-17C, thereby inhibiting the NF-κB signaling pathway, with an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. MOR-106 effectively reduces skin inflammation and related inflammatory factors in animal models of psoriasis and atopic dermatitis.

Eriodictyol (Standard) is a reference standard for research and analysis in studies involving Eriodictyol. 1. Eriodictyol (Huazhongilexone) is a flavonoid with anti-inflammatory and antioxidant activities. 2. Eriodictyol may possess antidiabetic properties through increasing glucose uptake and improving insulin resistance. 3. Eriodictyol may be a potential therapeutic resource for Atopic dermatitis and an adjunctive agent to control itchiness inAtopic dermatitis.